Jump Financial LLC Raises Stock Position in Innoviva, Inc. (NASDAQ:INVA)

Jump Financial LLC raised its position in Innoviva, Inc. (NASDAQ:INVAFree Report) by 281.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,995 shares of the biotechnology company’s stock after purchasing an additional 67,895 shares during the quarter. Jump Financial LLC owned about 0.14% of Innoviva worth $1,476,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets grew its position in Innoviva by 87.0% in the fourth quarter. BNP Paribas Financial Markets now owns 57,979 shares of the biotechnology company’s stock worth $930,000 after acquiring an additional 26,980 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Innoviva by 17.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 933,259 shares of the biotechnology company’s stock worth $14,969,000 after purchasing an additional 135,456 shares during the period. Victory Capital Management Inc. increased its position in shares of Innoviva by 14.1% during the 4th quarter. Victory Capital Management Inc. now owns 12,600 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,558 shares during the last quarter. Chase Investment Counsel Corp acquired a new position in Innoviva in the fourth quarter valued at about $1,090,000. Finally, SummerHaven Investment Management LLC boosted its stake in Innoviva by 1.2% during the fourth quarter. SummerHaven Investment Management LLC now owns 58,298 shares of the biotechnology company’s stock worth $935,000 after buying an additional 705 shares during the period. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. StockNews.com raised Innoviva from a “hold” rating to a “buy” rating in a research report on Friday, March 29th. TheStreet upgraded Innoviva from a “c” rating to a “b-” rating in a report on Thursday, February 29th.

Get Our Latest Stock Report on INVA

Innoviva Trading Down 1.7 %

Shares of INVA stock opened at $15.84 on Thursday. The stock has a market capitalization of $1.00 billion, a P/E ratio of 7.14 and a beta of 0.57. Innoviva, Inc. has a fifty-two week low of $12.22 and a fifty-two week high of $16.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.17 and a current ratio of 10.42. The company has a 50 day moving average price of $15.04 and a 200 day moving average price of $15.17.

Innoviva (NASDAQ:INVAGet Free Report) last posted its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.76 earnings per share for the quarter. The business had revenue of $85.84 million for the quarter. Innoviva had a return on equity of 28.94% and a net margin of 58.21%.

Innoviva Profile

(Free Report)

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Featured Articles

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVAFree Report).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.